Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Birmingham
About this trial
The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.
Eligibility criteria
Qualifiers
Biopsy proven relapsed or refractory CD20 positive, grade 1-3a follicular lymphoma (biopsy within 3 months of trial entry)
Aged 18 years or over
Advanced disease that in the opinion of the treating physician requires treatment
Patient suitable for standard available therapy at the Investigator's discretion
Disqualifiers
Current (or within 1 year) transformation to high grade lymphoma, including grade 3b follicular lymphoma (patients with historical high-grade transformation over 1 year ago are eligible)
Non-Fluorodeoxyglucose (FDG) avid disease
Prior allogenic stem cell transplantation (SCT) or solid organ transplant
Prior treatment with lenalidomide
Trial design
Treatments tested in this trial
- Epcoritamab
- Lenalidomide
- Rituximab
- Obinutuzumab
- Bendamustine
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
- Investigation agent 2
- Investigation agent 3
Treatment groups
284 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov